-
1
-
-
34548083672
-
Cytochrome P450 3A polymorphisms and immunosuppressive drugs: An update
-
Anglicheau D, Legendre C, Beaune P, et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: An update. Pharmacog-enomics 2007; 8: 835.
-
(2007)
Pharmacog-enomics
, vol.8
, pp. 835
-
-
Anglicheau, D.1
Legendre, C.2
Beaune, P.3
-
2
-
-
70349116090
-
Pharmacogenetics of calcineurin inhibitors in renal transplantation
-
Coto E, Tavira B. Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation 2009; 88: S62.
-
(2009)
Transplantation
, vol.88
-
-
Coto, E.1
Tavira, B.2
-
4
-
-
60849086797
-
Individualizationofimmunosuppres-sion: Concepts and rationale
-
Wavamunno MD, Chapman JR. Individualizationofimmunosuppres-sion: Concepts and rationale. Curr Opin Organ Transplant 2008; 13: 604.
-
(2008)
Curr Opin Organ Transplant
, vol.13
, pp. 604
-
-
Wavamunno, M.D.1
Chapman, J.R.2
-
5
-
-
33748057835
-
An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients
-
Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 2006; 112: 184.
-
(2006)
Pharmacol Ther
, vol.112
, pp. 184
-
-
Masuda, S.1
Inui, K.2
-
6
-
-
73349087877
-
Tacrolimus: Review of pharmacokinetics, pharmacodynamics, and pharmacogeneticstofacil-itate practitioners' understanding and offer strategies for educating patients and promoting adherence
-
Vicari-Christensen M, Repper S, Basile S, et al. Tacrolimus: Review of pharmacokinetics, pharmacodynamics, and pharmacogeneticstofacil-itate practitioners' understanding and offer strategies for educating patients and promoting adherence. Prog Transplant 2009; 19: 277.
-
(2009)
Prog Transplant
, vol.19
, pp. 277
-
-
Vicari-Christensen, M.1
Repper, S.2
Basile, S.3
-
8
-
-
3242772986
-
Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation
-
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623.
-
(2004)
Clin Pharmacokinet
, vol.43
, pp. 623
-
-
Staatz, C.E.1
Tett, S.E.2
-
9
-
-
38449094179
-
Metabolism of tacrolimus (FK506) and recent topicsinclin-ical pharmacokinetics
-
Iwasaki K. Metabolism of tacrolimus (FK506) and recent topicsinclin-ical pharmacokinetics. Drug Metab Pharmacokinet 2007; 22: 328.
-
(2007)
Drug Metab Pharmacokinet
, vol.22
, pp. 328
-
-
Iwasaki, K.1
-
10
-
-
33745487508
-
Active drug transport of immu-nosuppressants: New insights for pharmacokinetics and pharmacody-namics
-
Christians U, Strom T, Zhang YL, et al. Active drug transport of immu-nosuppressants: New insights for pharmacokinetics and pharmacody-namics. Ther Drug Monit 2006; 28: 39.
-
(2006)
Ther Drug Monit
, vol.28
, pp. 39
-
-
Christians, U.1
Strom, T.2
Zhang, Y.L.3
-
11
-
-
0028295725
-
Metabolism of FK506, a potent immunosuppressive agent,bycytochrome P4503A enzymesinrat, dog and human liver microsomes
-
Shiraga T, Matsuda H, Nagase K, et al. Metabolism of FK506, a potent immunosuppressive agent,bycytochrome P4503A enzymesinrat, dog and human liver microsomes. Biochem Pharmacol 1994; 47: 727.
-
(1994)
Biochem Pharmacol
, vol.47
, pp. 727
-
-
Shiraga, T.1
Matsuda, H.2
Nagase, K.3
-
12
-
-
0027418815
-
Human P-glycoprotein transports cyclosporin A and FK506
-
SaekiT,Ueda K,TanigawaraY,et al Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993. 268: 6077.
-
(1993)
J Biol Chem
, vol.268
, pp. 6077
-
-
Saeki, T.1
Ueda, K.2
Tanigawara, Y.3
-
13
-
-
0032986187
-
Low systemic exposure to tacrolimus correlates with acute rejection
-
Undre NA, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999; 31: 296.
-
(1999)
Transplant Proc
, vol.31
, pp. 296
-
-
Undre, N.A.1
Van Hooff, J.2
Christiaans, M.3
-
14
-
-
68449089526
-
Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection
-
Borobia AM, Romero I, Jimenez C, et al. Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. Ther Drug Monit 2009; 31: 436.
-
(2009)
Ther Drug Monit
, vol.31
, pp. 436
-
-
Borobia, A.M.1
Romero, I.2
Jimenez, C.3
-
15
-
-
65349115890
-
Opportunities to optimize tacrolimus therapy in solid organ transplantation: Report of the European consensus conference
-
Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: Report of the European consensus conference. Ther Drug Monit 2009; 31: 139.
-
(2009)
Ther Drug Monit
, vol.31
, pp. 139
-
-
Wallemacq, P.1
Armstrong, V.W.2
Brunet, M.3
-
16
-
-
77249158801
-
Effect of CYP3A and ABCB1 single nucleotide polymorphismsonthe pharmacokinetics and pharmacody-namics of calcineurin inhibitors: Part II
-
Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphismsonthe pharmacokinetics and pharmacody-namics of calcineurin inhibitors: Part II. Clin Pharmacokinet 2010; 49: 207.
-
(2010)
Clin Pharmacokinet
, vol.49
, pp. 207
-
-
Staatz, C.E.1
Goodman, L.K.2
Tett, S.E.3
-
17
-
-
77249125964
-
Effect of CYP3A and ABCB1 single nucleotide polymorphismsonthe pharmacokinetics and pharmacody-namics of calcineurin inhibitors: Part i
-
Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphismsonthe pharmacokinetics and pharmacody-namics of calcineurin inhibitors: Part I. Clin Pharmacokinet 2010; 49: 141.
-
(2010)
Clin Pharmacokinet
, vol.49
, pp. 141
-
-
Staatz, C.E.1
Goodman, L.K.2
Tett, S.E.3
-
18
-
-
65549149071
-
Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea
-
Jun KR, Lee W,Jang MS,etal. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Transplantation 2009; 87: 1225.
-
(2009)
Transplantation
, vol.87
, pp. 1225
-
-
Jun, K.R.1
Lee, W.2
Jang, M.S.3
-
19
-
-
40549112692
-
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients
-
Hesselink DA, van Schaik RH, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008; 18: 339.
-
(2008)
Pharmacogenet Genomics
, vol.18
, pp. 339
-
-
Hesselink, D.A.1
Van Schaik, R.H.2
Van Agteren, M.3
-
20
-
-
14044278166
-
Tacrolimus pharmaco-genetics: The CYP3A5*1 allele predicts low dose-normalized tacroli-mus blood concentrations in whites and South Asians
-
Macphee IA, Fredericks S, Mohamed M, et al. Tacrolimus pharmaco-genetics: The CYP3A5*1 allele predicts low dose-normalized tacroli-mus blood concentrations in whites and South Asians. Transplantation 2005; 79: 499.
-
(2005)
Transplantation
, vol.79
, pp. 499
-
-
MacPhee, I.A.1
Fredericks, S.2
Mohamed, M.3
-
21
-
-
0041831261
-
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharma-cokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
-
Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharma-cokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245.
-
(2003)
Clin Pharmacol Ther
, vol.74
, pp. 245
-
-
Hesselink, D.A.1
Van Schaik, R.H.2
Van Der Heiden, I.P.3
-
22
-
-
33846632909
-
CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients
-
Renders L, Frisman M, Ufer M, et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 2007; 81: 228.
-
(2007)
Clin Pharmacol Ther
, vol.81
, pp. 228
-
-
Renders, L.1
Frisman, M.2
Ufer, M.3
-
23
-
-
33749984168
-
CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: Guidelines from an experimental study
-
Haufroid V,WallemacqP,VanKerckhoveV, etal. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: Guidelines from an experimental study. Am J Transplant 2006; 6: 2706.
-
(2006)
Am J Transplant
, vol.6
, pp. 2706
-
-
Haufroid, V.1
Wallemacq, P.2
Van Kerckhove, V.3
-
24
-
-
34447549311
-
Tacrolimus pharma-cokinetics and pharmacogenetics: Influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms
-
Op den Buijsch RA, Christiaans MH, Stolk LM, et al. Tacrolimus pharma-cokinetics and pharmacogenetics: Influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol 2007; 21: 427.
-
(2007)
Fundam Clin Pharmacol
, vol.21
, pp. 427
-
-
Op Den Buijsch, R.A.1
Christiaans, M.H.2
Stolk, L.M.3
-
25
-
-
7044272257
-
Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients
-
Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78: 1182.
-
(2004)
Transplantation
, vol.78
, pp. 1182
-
-
Tsuchiya, N.1
Satoh, S.2
Tada, H.3
-
26
-
-
2942588886
-
The influence of pharmacoge-netics on the time to achieve target tacrolimus concentrations after kidney transplantation
-
MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacoge-netics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4: 914.
-
(2004)
Am J Transplant
, vol.4
, pp. 914
-
-
MacPhee, I.A.1
Fredericks, S.2
Tai, T.3
-
27
-
-
0242332169
-
Impact ofcytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients
-
Thervet E, Anglicheau D, King B, et al. Impact ofcytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76: 1233.
-
(2003)
Transplantation
, vol.76
, pp. 1233
-
-
Thervet, E.1
Anglicheau, D.2
King, B.3
-
28
-
-
36148985704
-
CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term ta-crolimus disposition and drug-related nephrotoxicity in renal recipients
-
Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term ta-crolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82: 711.
-
(2007)
Clin Pharmacol Ther
, vol.82
, pp. 711
-
-
Kuypers, D.R.1
De Jonge, H.2
Naesens, M.3
-
29
-
-
58149148271
-
Haplotypic structure of ABCB1/ MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients
-
Bandur S, Petrasek J, Hribova P, et al. Haplotypic structure of ABCB1/ MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation 2008; 86: 1206.
-
(2008)
Transplantation
, vol.86
, pp. 1206
-
-
Bandur, S.1
Petrasek, J.2
Hribova, P.3
-
30
-
-
33747085521
-
Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients
-
Roy JN, Barama A, Poirier C, et al. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 2006; 16: 659.
-
(2006)
Pharmacogenet Genomics
, vol.16
, pp. 659
-
-
Roy, J.N.1
Barama, A.2
Poirier, C.3
-
31
-
-
12144286933
-
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients
-
Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147.
-
(2004)
Pharmacogenetics
, vol.14
, pp. 147
-
-
Haufroid, V.1
Mourad, M.2
Van Kerckhove, V.3
-
32
-
-
65349104728
-
Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients
-
Press RR, Ploeger BA, den Hartigh J, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 2009; 31: 187.
-
(2009)
Ther Drug Monit
, vol.31
, pp. 187
-
-
Press, R.R.1
Ploeger, B.A.2
Den Hartigh, J.3
-
33
-
-
0038304548
-
Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients
-
Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14: 1889.
-
(2003)
J Am Soc Nephrol
, vol.14
, pp. 1889
-
-
Anglicheau, D.1
Verstuyft, C.2
Laurent-Puig, P.3
-
34
-
-
0037115210
-
Tacrolimus pharmacogenetics: Polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement
-
Macphee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: Polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486.
-
(2002)
Transplantation
, vol.74
, pp. 1486
-
-
MacPhee, I.A.1
Fredericks, S.2
Tai, T.3
-
35
-
-
27644467774
-
Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids
-
Mourad M, Mourad G, Wallemacq P, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005; 80: 977.
-
(2005)
Transplantation
, vol.80
, pp. 977
-
-
Mourad, M.1
Mourad, G.2
Wallemacq, P.3
-
36
-
-
33748710224
-
Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements
-
Fredericks S, Moreton M, Reboux S, et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation 2006; 82: 705.
-
(2006)
Transplantation
, vol.82
, pp. 705
-
-
Fredericks, S.1
Moreton, M.2
Reboux, S.3
-
37
-
-
79951510522
-
Association of single nucleotide polymorphisms and acute rejection
-
Oetting W, Schladt D, Israni I, et al. Association of single nucleotide polymorphisms and acute rejection.AmJTransplant2010; 10(suppl 4); 389.
-
(2010)
Am J Transplant
, vol.10
, Issue.SUPPL. 4
, pp. 389
-
-
Oetting, W.1
Schladt, D.2
Israni, I.3
-
38
-
-
0035133672
-
The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups
-
Mancinelli LM, FrassettoL, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups. Clin Pharmacol Ther 2001; 69: 24.
-
(2001)
Clin Pharmacol Ther
, vol.69
, pp. 24
-
-
Mancinelli, L.M.1
Frassetto, L.2
Floren, L.C.3
-
39
-
-
0026662551
-
Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat
-
Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20: 753.
-
(1992)
Drug Metab Dispos
, vol.20
, pp. 753
-
-
Sattler, M.1
Guengerich, F.P.2
Yun, C.H.3
-
41
-
-
33645864935
-
Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro
-
Dai Y, Hebert MF, Isoherranen N, et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34: 836.
-
(2006)
Drug Metab Dispos
, vol.34
, pp. 836
-
-
Dai, Y.1
Hebert, M.F.2
Isoherranen, N.3
-
42
-
-
59249101691
-
Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans
-
Perera MA, Thirumaran RK, Cox NJ, et al. Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharma-cogenomics J 2009; 9: 49.
-
(2009)
Pharma-cogenomics J
, vol.9
, pp. 49
-
-
Perera, M.A.1
Thirumaran, R.K.2
Cox, N.J.3
-
43
-
-
77952585319
-
Optimization of initial tacroli-mus dose using pharmacogenetic testing
-
Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacroli-mus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010; 87: 721.
-
(2010)
Clin Pharmacol Ther
, vol.87
, pp. 721
-
-
Thervet, E.1
Loriot, M.A.2
Barbier, S.3
-
44
-
-
77949873283
-
Genetic and clinical predictors of warfarin dose requirements in African Americans
-
Cavallari LH, Langaee TY, Momary KM, et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87: 459.
-
(2010)
Clin Pharmacol Ther
, vol.87
, pp. 459
-
-
Cavallari, L.H.1
Langaee, T.Y.2
Momary, K.M.3
-
45
-
-
77949874684
-
Apolymorphisminthe VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans
-
VooraD,Koboldt DC, King CR, etal.Apolymorphisminthe VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87: 445.
-
(2010)
Clin Pharmacol Ther
, vol.87
, pp. 445
-
-
Voora, D.1
Koboldt, D.C.2
King, C.R.3
-
46
-
-
10344264967
-
Pharmacokinetics of immunosup-pressants: Aperspectiveonethnic differences
-
Dirks NL, Huth B, Yates CR, et al. Pharmacokinetics of immunosup-pressants: Aperspectiveonethnic differences.IntJClin Pharmacol Ther 2004; 42: 701.
-
(2004)
Int J Clin Pharmacol Ther
, vol.42
, pp. 701
-
-
Dirks, N.L.1
Huth, B.2
Yates, C.R.3
-
47
-
-
0032570530
-
Racial differences in renal transplantation after immuno-suppression with tacrolimus versus cyclosporine
-
FK506 Kidney Transplant Study Group
-
Neylan JF. Racial differences in renal transplantation after immuno-suppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998; 65: 515.
-
(1998)
Transplantation
, vol.65
, pp. 515
-
-
Neylan, J.F.1
-
48
-
-
0031859573
-
Effect of race and immunosuppression in renal transplantation: Three-year survival results from a US multicenter, randomized trial
-
FK506 Kidney Transplant Study Group
-
Neylan JF. Effect of race and immunosuppression in renal transplantation: Three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. Transplant Proc 1998; 30: 1355.
-
(1998)
Transplant Proc
, vol.30
, pp. 1355
-
-
Neylan, J.F.1
-
49
-
-
75749114491
-
CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacroli-mus in bioequivalence study
-
Yong Chung J, Jung Lee Y, Bok Jang S, et al. CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacroli-mus in bioequivalence study. Ther Drug Monit 2010; 32: 67.
-
(2010)
Ther Drug Monit
, vol.32
, pp. 67
-
-
Yong Chung, J.1
Jung Lee, Y.2
Bok Jang, S.3
-
50
-
-
34547687359
-
Tacrolimus in diabetic kidney transplant recipients: Pharmacokinetics and application of a limited sampling strategy
-
Mendonza AE, Zahir H, Gohh RY, et al. Tacrolimus in diabetic kidney transplant recipients: Pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2007; 29: 391.
-
(2007)
Ther Drug Monit
, vol.29
, pp. 391
-
-
Mendonza, A.E.1
Zahir, H.2
Gohh, R.Y.3
-
51
-
-
11844249410
-
Time to reach tacrolimus maximum blood concentration, mean residence time, and acute renal allograft rejection: An open-label, prospective, pharmacokinetic study in adult recipients
-
Kuypers DR, Vanrenterghem Y. Time to reach tacrolimus maximum blood concentration, mean residence time, and acute renal allograft rejection: An open-label, prospective, pharmacokinetic study in adult recipients. Clin Ther 2004; 26: 1834.
-
(2004)
Clin Ther
, vol.26
, pp. 1834
-
-
Kuypers, D.R.1
Vanrenterghem, Y.2
-
52
-
-
0036913473
-
Population pharmacokinetics of tacrolimus in adult kidney transplant recipients
-
Staatz CE, Willis C, Taylor PJ, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002; 72: 660.
-
(2002)
Clin Pharmacol Ther
, vol.72
, pp. 660
-
-
Staatz, C.E.1
Willis, C.2
Taylor, P.J.3
-
53
-
-
0242351679
-
Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation
-
Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003; 18: 2409.
-
(2003)
Nephrol Dial Transplant
, vol.18
, pp. 2409
-
-
Anglicheau, D.1
Flamant, M.2
Schlageter, M.H.3
-
54
-
-
61349142451
-
Tacrolimus pharma-cokinetic drug interactions: Effectofprednisone, mycophenolic acid or sirolimus
-
Park SI, Felipe CR, Pinheiro-Machado PG, et al. Tacrolimus pharma-cokinetic drug interactions: Effectofprednisone, mycophenolic acid or sirolimus. Fundam Clin Pharmacol 2009; 23: 137.
-
(2009)
Fundam Clin Pharmacol
, vol.23
, pp. 137
-
-
Park, S.I.1
Felipe, C.R.2
Pinheiro-Machado, P.G.3
-
55
-
-
58749088941
-
Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring
-
Kuypers DR. Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. Ann Transplant 2008; 13: 11.
-
(2008)
Ann Transplant
, vol.13
, pp. 11
-
-
Kuypers, D.R.1
-
56
-
-
48249120712
-
Corticosteroid interactions with cyclo-sporine tacrolimus mycophenolate and sirolimus: Fact or fiction?
-
Lam S, Partovi N, Ting LS, et al. Corticosteroid interactions with cyclo-sporine, tacrolimus, mycophenolate, and sirolimus: Fact or fiction? Ann Pharmacother 2008; 42: 1037.
-
(2008)
Ann Pharmacother
, vol.42
, pp. 1037
-
-
Lam, S.1
Partovi, N.2
Ting, L.S.3
-
57
-
-
0036290197
-
Pharmacokinetic interaction between tacrolimus and diltiazem: Dose-response relationship in kidney and liver transplant recipients
-
Jones TE, Morris RG. Pharmacokinetic interaction between tacrolimus and diltiazem: Dose-response relationship in kidney and liver transplant recipients. Clin Pharmacokinet 2002; 41: 381.
-
(2002)
Clin Pharmacokinet
, vol.41
, pp. 381
-
-
Jones, T.E.1
Morris, R.G.2
-
58
-
-
0036380025
-
Mechanisms of clinically relevant drug interactions associated with tacrolimus
-
Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmaco-kinet 2002; 41: 813.
-
(2002)
Clin Pharmaco-kinet
, vol.41
, pp. 813
-
-
Christians, U.1
Jacobsen, W.2
Benet, L.Z.3
-
59
-
-
0036360906
-
Drug interactions with tacrolimus
-
van Gelder T. Drug interactions with tacrolimus. Drug Saf 2002; 25: 707.
-
(2002)
Drug Saf
, vol.25
, pp. 707
-
-
Van Gelder, T.1
-
60
-
-
16444367741
-
Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients
-
Kim JS, Aviles DH, Silverstein DM, et al. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 2005; 9: 162.
-
(2005)
Pediatr Transplant
, vol.9
, pp. 162
-
-
Kim, J.S.1
Aviles, D.H.2
Silverstein, D.M.3
-
61
-
-
0041317355
-
Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids
-
Hesselink DA, Ngyuen H, Wabbijn M, et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br J Clin Pharmacol 2003; 56: 327.
-
(2003)
Br J Clin Pharmacol
, vol.56
, pp. 327
-
-
Hesselink, D.A.1
Ngyuen, H.2
Wabbijn, M.3
-
62
-
-
70149105801
-
CYP3A5*1/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole
-
Chandel N, Aggarwal PK, Minz M, et al. CYP3A5*1/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole. Pharmacogenet Genomics 2009; 19: 458.
-
(2009)
Pharmacogenet Genomics
, vol.19
, pp. 458
-
-
Chandel, N.1
Aggarwal, P.K.2
Minz, M.3
-
63
-
-
53549126614
-
Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients
-
Kuypers DR, de Jonge H, Naesens M, et al. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 2008; 18: 861.
-
(2008)
Pharmacogenet Genomics
, vol.18
, pp. 861
-
-
Kuypers, D.R.1
De Jonge, H.2
Naesens, M.3
-
64
-
-
77954623148
-
Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure
-
Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68.
-
(2010)
Transplantation
, vol.90
, pp. 68
-
-
Gaston, R.S.1
Cecka, J.M.2
Kasiske, B.L.3
-
65
-
-
67650941470
-
Use of cardioprotective medications in kidney transplant recipients
-
Gaston RS, Kasiske BL, Fieberg AM, et al. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant 2009; 9: 1811.
-
(2009)
Am J Transplant
, vol.9
, pp. 1811
-
-
Gaston, R.S.1
Kasiske, B.L.2
Fieberg, A.M.3
-
66
-
-
75149136028
-
Pathological and clinical characterization of the 'troubled transplant' Data from the DeKAF study
-
Gourishankar S, Leduc R, Connett J, et al. Pathological and clinical characterization of the 'troubled transplant': Data from the DeKAF study. Am J Transplant 2010; 10: 324.
-
(2010)
Am J Transplant
, vol.10
, pp. 324
-
-
Gourishankar, S.1
Leduc, R.2
Connett, J.3
-
67
-
-
0016916438
-
Prediction of creatinine clearance from serum creatinine
-
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
-
(1976)
Nephron
, vol.16
, pp. 31
-
-
Cockcroft, D.W.1
Gault, M.H.2
-
68
-
-
52449099461
-
Genomic variation in myeloma: Design, content, and initial application of the bank on a cure SNP panel to detect associations with progression-free survival
-
Van Ness B, Ramos C, Haznadar M, et al. Genomic variation in myeloma: Design, content, and initial application of the bank on a cure SNP panel to detect associations with progression-free survival. BMC Med 2008; 6: 26.
-
(2008)
BMC Med
, vol.6
, pp. 26
-
-
Van Ness, B.1
Ramos, C.2
Haznadar, M.3
-
69
-
-
0037685262
-
Multiplexed genotyping with sequence-tagged molecular inversion probes
-
Hardenbol P, Baner J, Jain M, et al. Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat Biotechnol 2003; 21: 673.
-
(2003)
Nat Biotechnol
, vol.21
, pp. 673
-
-
Hardenbol, P.1
Baner, J.2
Jain, M.3
-
70
-
-
70350638990
-
A new measure of the effective number of tests,a practical tool for comparing families of non-independent significance tests
-
Galwey NW. A new measure of the effective number of tests,a practical tool for comparing families of non-independent significance tests. Genet Epidemiol 2009; 33: 559.
-
(2009)
Genet Epidemiol
, vol.33
, pp. 559
-
-
Galwey, N.W.1
|